Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations
about
Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injuryIs lipid signaling through cannabinoid 2 receptors part of a protective system?CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytesA cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized ratsCB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model.Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment.Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death.Endocannabinoids in cerebrovascular regulation.Modulating the endocannabinoid system in human health and disease--successes and failuresAntagonist-elicited cannabis withdrawal in humansCannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferationMechanisms of endothelial dysfunction in obesity-associated hypertension.The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.Endocannabinoids and cardiac contractile function: pathophysiological implications.The therapeutic potential of novel cannabinoid receptorsThe emerging role of the endocannabinoid system in cardiovascular disease.Mid-ventricular variant takotsubo cardiomyopathy associated with Cannabinoid Hyperemesis Syndrome: a case reportMechanisms of obesity-induced hypertension.Endocannabinoids and the cardiovascular response to stress.Inflammation and fibrogenesis in steatohepatitis.Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment.Cannabinoid-Induced Hyperemesis: A Conundrum-From Clinical Recognition to Basic Science Mechanisms.The endocannabinoid system in the baboon (Papio spp.) as a complex framework for developmental pharmacology.Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia–reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS.Factors influencing the regional haemodynamic responses to methanandamide and anandamide in conscious rats.Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?Cardiovascular Complications of Marijuana and Related Substances: A Review.Chronic inhibition of fatty acid amide hydrolase by URB597 produces differential effects on cardiac performance in normotensive and hypertensive rats.Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors.The endocannabinoid system and emotional processing: pathophysiology and therapeutic potential.Endocan in hypertension and cardiovascular disease.
P2860
Q24595633-0424AB14-A9A7-4EFB-95BD-FE93859C3BAEQ24633122-0C80CEF9-FAC4-44BC-9196-ECE56DD5304BQ24649936-FFACF202-823D-4B98-A12E-3CB8EA3B4596Q34095081-2AB05F25-BA7C-40D8-B366-4767A03952C6Q34098258-B5F70731-0CE0-4487-9E0F-8E6535837881Q34534223-4639FAA5-2FBB-49F9-8EDA-E3C80B052EC7Q34851941-F054751B-45CD-440E-BD99-E5682504FC9DQ36895795-EAECCC2D-962C-4667-840C-B270BA59FCC2Q36933683-37CC8865-9C71-4CE2-A506-990DCA9476E0Q37029517-2A1C1012-EBEA-4AF0-8C2F-4730DD52A063Q37105857-EE78C2EA-08D1-49F9-8302-A66E9CE5C148Q37371166-97B22253-E968-4EE7-B37F-56F674A74204Q37375986-FDBA0719-12A6-42A1-8E25-1F342363548EQ37401757-390C4E98-A7C5-4510-B25C-C6E15F2B154FQ37402927-1239C213-4DAF-4F7B-BEA7-62016B08DD46Q37439386-DF35CA3E-CF7D-42F3-A2BF-AD570EEA9F1FQ37720858-F4B6CAB5-57B1-4C19-9257-1427A17605E5Q37742440-50D9C338-DFFF-4C10-BA6A-AC6D23C6FBB0Q37894978-8EEA1EDA-A160-4F03-B2D8-1D8D76A0117DQ37981867-1848F84D-6076-4911-B7D6-1C2953A67BAFQ38255902-0CDC6203-3EFC-466B-B54C-E1A2031F1EA3Q38974381-3A3A67BF-EA2F-48D2-8A4F-7578F589CEABQ39666956-944C788C-63E3-48A8-8E6B-575AC5ED35BEQ39784439-D640EB0F-7FFE-4B8E-B6EA-7DD0DB7C55DCQ42000652-641E732A-6B45-4374-A3D0-49940E6D9A6EQ43145354-D3BBDF9F-9574-47EA-B2BD-4E38C2CFA706Q47316420-8606AB83-8BE1-4444-B89D-2E9A9FD2601AQ48238653-CF0AF352-694E-4F8E-A16E-71991078BBD5Q48915385-16CE9DC7-89F0-470A-A820-C58B83FCF5D4Q50592444-913D11C1-2C78-4219-92E0-59EEE60CE6A3Q54456960-F3949A15-1429-4342-9D10-BD990B5123DB
P2860
Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Modulation of the endocannabin ...... utic potential and limitations
@en
type
label
Modulation of the endocannabin ...... utic potential and limitations
@en
prefLabel
Modulation of the endocannabin ...... utic potential and limitations
@en
P2093
P2860
P1433
P1476
Modulation of the endocannabin ...... utic potential and limitations
@en
P2093
George Kunos
Grzegorz Godlewski
Rajesh Mohanraj
Sándor Bátkai
P2860
P304
P356
10.1161/HYPERTENSIONAHA.105.063651
P407
P577
2008-09-08T00:00:00Z